Australia markets closed

Centogene N.V. (CNTG)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.3050-0.0150 (-1.14%)
At close: 03:46PM EST
1.3100 +0.00 (+0.38%)
After hours: 04:08PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.3200
Bid1.3000 x 1000
Ask1.3500 x 2900
Day's range1.2903 - 1.3500
52-week range0.6800 - 4.9400
Avg. volume29,125
Market cap35.341M
Beta (5Y monthly)-1.08
PE ratio (TTM)N/A
EPS (TTM)-2.1970
Earnings date28 Mar 2023 - 03 Apr 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.51
  • Business Wire

    Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

    SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. & ROSTOCK, Germany & BERLIN, January 10, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rar

  • GlobeNewswire

    CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics

    Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development, and commercialization for Parkinson’s disease (PD)The Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of disease progression, diagnosis, and treatment for patientsHaving recently reached a significant milestone of testing over 12,500 participants, the study now aims to recruit and genetic

  • PR Newswire

    Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development

    Premier Research, whose mission is to help the most innovative biotech and medtech companies take their best ideas from concept to commercialization, and Centogene N.V. [Nasdaq: CNTG], the essential life science partner for data-driven answers in rare and neurodegenerative diseases, have announced a strategic partnership to provide end-to-end support in rare disease clinical trials. The collaboration aims to improve patient identification, stratification, recruitment, and enrollment, thereby inc